NO20075574L - Krystallinsk form av en quinolinonkarboksamidforbindelse - Google Patents

Krystallinsk form av en quinolinonkarboksamidforbindelse

Info

Publication number
NO20075574L
NO20075574L NO20075574A NO20075574A NO20075574L NO 20075574 L NO20075574 L NO 20075574L NO 20075574 A NO20075574 A NO 20075574A NO 20075574 A NO20075574 A NO 20075574A NO 20075574 L NO20075574 L NO 20075574L
Authority
NO
Norway
Prior art keywords
crystalline form
carboxamide compound
salt forms
crystalline
disclosed
Prior art date
Application number
NO20075574A
Other languages
English (en)
Other versions
NO339699B1 (no
Inventor
Paul Ross Fatheree
Daniel Genov
Robert S Chao
Adam A Goldblum
S Derek Turner
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of NO20075574L publication Critical patent/NO20075574L/no
Publication of NO339699B1 publication Critical patent/NO339699B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det er beskrevet et krystallinsk hydrokloridsalt av l-isopropyl-2-okso-l,2-dihydroquinolin-3-karboksylsyre {(lS,3R,5R)-8-[(R)-2-hydroksy-3-(metansulfonylmetylamino)propyl]-8-azabicyklo[3.2.1]okt-3-yl} amid eller et solvat derav. Det er også beskrevet farmasøytiske preparater omfattende slike krystallinske saltformer, fremgangsmåter for anvendelse av slike krystallinske saltformer for å behandle sykdommer forbundet med 5-HT4 reseptoraktivitet, og fremgangsmåter som er nyttige for fremstilling av slike krystallinske saltformer.
NO20075574A 2005-04-06 2007-11-02 Krystallinsk form av en quinolinonkarboksamidforbindelse NO339699B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06
PCT/US2006/012978 WO2006108127A2 (en) 2005-04-06 2006-04-05 Crystalline form of a quinolinone-carboxamide compound

Publications (2)

Publication Number Publication Date
NO20075574L true NO20075574L (no) 2007-11-02
NO339699B1 NO339699B1 (no) 2017-01-23

Family

ID=37074104

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075574A NO339699B1 (no) 2005-04-06 2007-11-02 Krystallinsk form av en quinolinonkarboksamidforbindelse

Country Status (29)

Country Link
US (4) US7728004B2 (no)
EP (1) EP1874766B1 (no)
JP (2) JP5230407B2 (no)
KR (1) KR101322873B1 (no)
CN (1) CN101151264B (no)
AR (2) AR053208A1 (no)
AT (1) ATE479682T1 (no)
AU (1) AU2006232129B2 (no)
BR (1) BRPI0610657A2 (no)
CA (1) CA2603654C (no)
CY (1) CY1111275T1 (no)
DE (1) DE602006016586D1 (no)
DK (1) DK1874766T3 (no)
EA (1) EA012115B1 (no)
ES (1) ES2350495T3 (no)
HR (1) HRP20100629T1 (no)
IL (1) IL186023A (no)
MA (1) MA29403B1 (no)
MX (1) MX2007012438A (no)
MY (1) MY151075A (no)
NO (1) NO339699B1 (no)
NZ (1) NZ561900A (no)
PE (1) PE20061310A1 (no)
PL (1) PL1874766T3 (no)
PT (1) PT1874766E (no)
SI (1) SI1874766T1 (no)
TW (1) TWI377206B (no)
WO (1) WO2006108127A2 (no)
ZA (1) ZA200708071B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
EP1807423B1 (en) 2004-11-05 2009-05-20 Theravance, Inc. Quinolinone-carboxamide compounds
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
AU2008254999A1 (en) * 2007-05-17 2008-11-27 Theravance, Inc. Prokinetic agent for bowel preparation
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
SI2225230T1 (sl) * 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CA2758321A1 (en) 2009-04-13 2010-10-21 Theravance, Inc. 5-ht4 receptor agonist compounds for treatment of cognitive disorders
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
WO2013112804A1 (en) 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
JP6963896B2 (ja) 2013-11-12 2021-11-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
BR112020000482A2 (pt) 2017-07-31 2020-07-21 Theravance Biopharma R&D Ip, Llc métodos de tratamento de sintomas de gastroparesia usando velusetrag
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
EP4590303A1 (en) * 2022-09-20 2025-07-30 Alfasigma S.p.A. Velusetrag for use in the treatment of chronic intestinal pseudo-obstruction (cipo)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) * 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
DE69113284T2 (de) * 1990-12-28 1996-02-22 Kyowa Hakko Kogyo Co., Ltd., Tokio/Tokyo Chinolinderivat.
EP0670319A4 (en) * 1992-11-20 1996-01-17 Thaisho Pharmaceutical Co Ltd HETEROCYCLIC COMPOUNDS.
JP3829879B2 (ja) * 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
DE602004026095D1 (de) 2003-11-24 2010-04-29 Pfizer Chinoloncarbonsäureverbindungen mit 5-ht4-rezeptoragonistischer wirkung
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
EP1807423B1 (en) * 2004-11-05 2009-05-20 Theravance, Inc. Quinolinone-carboxamide compounds
WO2006088988A1 (en) 2005-02-17 2006-08-24 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
NZ560828A (en) * 2005-03-02 2011-01-28 Theravance Inc Quinolinone compounds as 5-HT4 receptor agonists
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Also Published As

Publication number Publication date
KR101322873B1 (ko) 2013-10-30
EA200702161A1 (ru) 2008-04-28
CN101151264A (zh) 2008-03-26
US7728004B2 (en) 2010-06-01
EP1874766A2 (en) 2008-01-09
DE602006016586D1 (de) 2010-10-14
WO2006108127A2 (en) 2006-10-12
HK1110866A1 (en) 2008-07-25
TW200643020A (en) 2006-12-16
MY151075A (en) 2014-03-31
US9126994B2 (en) 2015-09-08
US20160095849A1 (en) 2016-04-07
PT1874766E (pt) 2010-11-30
ATE479682T1 (de) 2010-09-15
EA012115B1 (ru) 2009-08-28
KR20070116988A (ko) 2007-12-11
US20060229332A1 (en) 2006-10-12
DK1874766T3 (da) 2010-12-06
EP1874766B1 (en) 2010-09-01
TWI377206B (en) 2012-11-21
JP5230407B2 (ja) 2013-07-10
PL1874766T3 (pl) 2011-02-28
JP2008535848A (ja) 2008-09-04
AR053208A1 (es) 2007-04-25
NZ561900A (en) 2010-12-24
CN101151264B (zh) 2011-07-06
PE20061310A1 (es) 2007-01-23
WO2006108127A3 (en) 2007-01-04
AU2006232129A1 (en) 2006-10-12
AU2006232129B2 (en) 2012-07-12
ZA200708071B (en) 2008-10-29
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
SI1874766T1 (sl) 2010-12-31
MX2007012438A (es) 2007-12-05
IL186023A0 (en) 2008-01-20
US20140256769A1 (en) 2014-09-11
MA29403B1 (fr) 2008-04-01
BRPI0610657A2 (pt) 2010-07-13
ES2350495T3 (es) 2011-01-24
CY1111275T1 (el) 2015-08-05
AR110019A2 (es) 2019-02-13
CA2603654A1 (en) 2006-10-12
JP2012153725A (ja) 2012-08-16
HRP20100629T1 (hr) 2010-12-31
US20100197728A1 (en) 2010-08-05
NO339699B1 (no) 2017-01-23
IL186023A (en) 2011-09-27
CA2603654C (en) 2014-05-27

Similar Documents

Publication Publication Date Title
NO20075574L (no) Krystallinsk form av en quinolinonkarboksamidforbindelse
WO2011139684A3 (en) Nicotine-containing pharmaceutical compositions
MA30694B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
JO2787B1 (en) Alternative amide derivatives and methods of use
WO2009155527A3 (en) Phosphatidylinositol 3 kinase inhibitors
HUP0301625A2 (hu) Réztartalmú amin-oxidáz inhibitor hatású 1,3,4-oxadiazin-vegyületek, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
BRPI0509761B8 (pt) compostos de quinolinona-carboxamida como agonistas de receptor de 5-ht4, composição farmacêutica, uso dos referidos compostos e seu processo de preparação
WO2007040438A3 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
ATE517882T1 (de) Chinolinderivate
NO20076481L (no) Benzimidazol-karboksamidforbindelser som 5-HT4 receptorantagonister
NO20050164L (no) Nye quinuklidin-amid-derivater
EA200601364A1 (ru) Производные хинолина и их применение в качестве ингибиторов микобактерий
WO2011126910A3 (en) Compositions and methods for the treatment of somatosensory disorders
AP2001002358A0 (en) Salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4- pyrrolidin-1-yl-butyl)ureido]-isothiazole-4-carboxilic acid amide and method of production.
EA200801245A1 (ru) [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины и формы и способы, связанные с ними
MX2012003720A (es) N-((1r,2s,5r)-5-(tert-butilamino)-2-((s)-3-(7-tert-butilpirazolo[ 1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)a cetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos.
NO20090190L (no) Modulatorer av kjemokin reseptor aktivitet, krystallinske former og fremgangsmate
NO20090256L (no) Modulatorer for kjemokine reseptoraktivitet, krystallinske former og prosesser
EA200901474A1 (ru) Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе
TWI644914B (zh) １，２，４－三唑并［４，３－ａ］吡啶化合物及其作為ＭＧＬＵＲ２受體之正向異位調節劑的用途
NO20074622L (no) Metabolitter for NK-1 antagonister for brekninger
HRP20120231T1 (hr) Upotreba derivata indola kao aktivatora nurr-1 u liječenju parkinsonove bolesti
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister
TW200640921A (en) Crystalline form of an indazole-carboxamide compound
EP3302466A1 (en) 3-(phenyl)-n-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of cftr protein mediated diseases

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: THERAVANCE BIOPHARMA R&D IP, US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: THERAVANCE BIOPHARMA R&D IP, US

MM1K Lapsed by not paying the annual fees